Float Short %

23.34

Margin Of Safety %

-42

Put/Call OI Ratio

0.54

EPS Next Q Diff

-0.24

EPS Last/This Y

1.91

EPS This/Next Y

-3.18

Price

23.46

Target Price

24.22

Analyst Recom

1.18

Performance Q

98.48

Relative Volume

1.27

Beta

1.23

Ticker: STOK

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	STOK	18.22	0.30	0.23	11496
2025-08-18	STOK	18.53	0.24	0.37	9333
2025-08-19	STOK	18.49	0.25	0.79	9354
2025-08-20	STOK	19.33	0.27	2.64	9534
2025-08-21	STOK	19.67	0.31	0.14	9840
2025-08-22	STOK	19.57	0.31	0.07	10009
2025-08-25	STOK	18.87	0.33	2.19	10169
2025-08-26	STOK	19.28	0.35	0.94	10357
2025-08-27	STOK	19.3	0.35	2.11	10362
2025-08-28	STOK	19.78	0.37	2.24	10536
2025-08-29	STOK	19.76	0.42	12.53	10897
2025-09-02	STOK	19.57	0.45	0.81	11123
2025-09-03	STOK	19.71	0.46	2.52	11341
2025-09-04	STOK	19.64	0.47	0.07	11483
2025-09-05	STOK	20.67	0.47	0.03	11521
2025-09-08	STOK	21.99	0.45	0.05	11819
2025-09-09	STOK	22.07	0.46	5.91	11685
2025-09-10	STOK	22.67	0.50	0.45	12006
2025-09-11	STOK	23.95	0.50	2.80	12071
2025-09-12	STOK	23.44	0.54	0.10	12380
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	STOK	18.19	-16.8	-	0.35
2025-08-18	STOK	18.52	-16.8	-	0.35
2025-08-19	STOK	18.49	-25.5	-	0.26
2025-08-20	STOK	19.31	-25.5	-	0.26
2025-08-21	STOK	19.67	-25.5	-	0.26
2025-08-22	STOK	19.55	-25.5	-	0.26
2025-08-25	STOK	18.88	-25.5	-	0.26
2025-08-26	STOK	19.37	-25.5	-	0.26
2025-08-27	STOK	19.28	-25.5	-	0.26
2025-08-28	STOK	19.77	-25.5	-	0.26
2025-08-29	STOK	19.75	-25.5	-	0.26
2025-09-02	STOK	19.57	-25.5	-	0.26
2025-09-03	STOK	19.78	-25.5	-	0.26
2025-09-04	STOK	19.62	-25.5	-	0.26
2025-09-05	STOK	20.68	-25.5	-	0.26
2025-09-08	STOK	21.99	-25.5	-	0.26
2025-09-09	STOK	22.07	-25.5	-	0.26
2025-09-10	STOK	22.67	-25.5	-	0.26
2025-09-11	STOK	23.88	-25.5	-	0.26
2025-09-12	STOK	23.46	-25.5	-	0.26
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	STOK	-25.95	-1.36	24.83
2025-08-18	STOK	-26.04	2.41	24.89
2025-08-19	STOK	-25.83	2.41	24.89
2025-08-20	STOK	-25.94	2.41	24.89
2025-08-21	STOK	-25.94	2.41	24.89
2025-08-22	STOK	-25.94	2.41	24.90
2025-08-25	STOK	-25.86	4.52	24.89
2025-08-26	STOK	-25.90	4.52	24.89
2025-08-27	STOK	-25.90	4.52	24.37
2025-08-28	STOK	-25.90	4.52	24.37
2025-08-29	STOK	-25.90	4.52	24.37
2025-09-02	STOK	-25.90	12.06	24.37
2025-09-03	STOK	-25.90	12.06	24.37
2025-09-04	STOK	-26.45	12.06	24.37
2025-09-05	STOK	-26.45	12.06	24.37
2025-09-08	STOK	-26.45	12.30	24.33
2025-09-09	STOK	-26.63	12.30	24.33
2025-09-10	STOK	-26.63	12.30	24.33
2025-09-11	STOK	-26.63	12.30	23.34
2025-09-12	STOK	-26.63	12.30	23.34
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.4

Avg. EPS Est. Current Quarter

-0.59

Avg. EPS Est. Next Quarter

-0.64

Insider Transactions

-26.63

Institutional Transactions

12.3

Beta

1.23

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

13.57

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

67.2

Max Drawdown 5-Year %

-95.2

Target Price

24.22

P/E

27.76

Forward P/E

PEG

P/S

6.43

P/B

3.83

P/Free Cash Flow

21.02

EPS

0.84

Average EPS Est. Cur. Y

0.26

EPS Next Y. (Est.)

-2.92

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

26.26

Relative Volume

1.27

Return on Equity vs Sector %

-9.2

Return on Equity vs Industry %

3.9

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.18

EBIT Estimation

Stoke Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 128

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase I/II clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

stock quote shares STOK – Stoke Therapeutics, Inc. Stock Price stock today

news today STOK – Stoke Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch STOK – Stoke Therapeutics, Inc. yahoo finance google finance

stock history STOK – Stoke Therapeutics, Inc. invest stock market

stock prices STOK premarket after hours

ticker STOK fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: STOK

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y